Lumos Diagnostics Holdings Ltd.ASX: LDX

Lumos Diagnostics FY22 First Half Year Results

· Issued by Lumos Diagnostics Holdings Ltd.

Filed with ASX · · 4 pages · English

• FebriDx® application for regulatory clearance in the U.S. remains on track for decision from the FDA in H2 FY2022. • Cash 31 December 2021 US$10.5 million Melbourne, VIC. (28 February 2022)-Lumos Diagnostics(ASX:LDX, “Lumos” or the “Company”), a leader in rapid point-of-care (POC) diagnostic technologies, today has announced its financial results for the FY2022 half year ending 31 December 2021.

Lumos Diagnostics Holdings Ltd. on 6ix

Earlier from Lumos Diagnostics

Later from Lumos Diagnostics

All Lumos Diagnostics news releases